Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study Company expects to resubmit NDA for oliceridine in Q1 2020  Acute migraine proof-of-concept study for TRV250 initiated  Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...